Genetic modification of adeno-associated viral vector type 2 capsid enhances gene transfer efficiency in polarized human airway epithelial cells.
Cystic fibrosis (CF) is a common genetic disease characterized by defects in the expression of the CF transmembrane conductance regulator (CFTR) gene. Gene therapy offers better hope for the treatment of CF. Adeno-associated viral (AAV) vectors are capable of stable expression with low immunogenicity. Despite their potential in CF gene therapy, gene transfer efficiency by AAV is limited because of pathophysiological barriers in these patients. Although a few AAV serotypes have shown better transduction compared with the AAV2-based vectors, gene transfer efficiency in human airway epithelium has still not reached therapeutic levels. To engineer better AAV vectors for enhanced gene delivery in human airway epithelium, we developed and characterized mutant AAV vectors by genetic capsid modification, modeling the well-characterized AAV2 serotype. We genetically incorporated putative high-affinity peptide ligands to human airway epithelium on the GH loop region of AAV2 capsid protein. Six independent mutant AAV were constructed, containing peptide ligands previously reported to bind with high affinity for known and unknown receptors on human airway epithelial cells. The vectors were tested on nonairway cells and nonpolarized and polarized human airway epithelial cells for enhanced infectivity. One of the mutant vectors, with the peptide sequence THALWHT, not only showed the highest transduction in undifferentiated human airway epithelial cells but also indicated significant transduction in polarized cells. Interestingly, this modified vector was also able to infect cells independently of the heparan sulfate proteoglycan receptor. Incorporation of this ligand on other AAV serotypes, which have shown improved gene transfer efficiency in the human airway epithelium, may enhance the application of AAV vectors in CF gene therapy.
White
April F
AF
Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Mazur
Marina
M
Sorscher
Eric J
EJ
Zinn
Kurt R
KR
Ponnazhagan
Selvarangan
S
D001483:Base Sequence; D001980:Bronchi / Q000378:metabolism* / Q000473:pathology; D002213:Capsid; D002478:Cells, Cultured; D003550:Cystic Fibrosis / Q000473:pathology / Q000628:therapy; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics; D017931:DNA Primers; D000229:Dependovirus / Q000235:genetics*; D004847:Epithelial Cells / Q000378:metabolism; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D014161:Transduction, Genetic
D017931:DNA Primers; D019005:Cystic Fibrosis Transmembrane Conductance Regulator
J Virol. 1997 Feb;71(2):1341-52
8995658
Proc Natl Acad Sci U S A. 2003 May 13;100(10):6081-6
12716974
J Virol. 2001 Jul;75(14):6615-24
11413329
Cancer Res. 1984 Sep;44(9):3961-9
6744312
J Cell Biol. 1994 May;125(3):583-94
8175882
Hum Gene Ther. 2001 Oct 10;12(15):1907-16
11589832
J Drug Target. 2002 Feb;10(1):31-40
11996084
Am J Physiol. 1994 May;266(5 Pt 1):L493-501
7515578
J Virol. 2003 Oct;77(20):11072-81
14512555
J Biol Chem. 2004 May 21;279(21):22578-84
15066992
J Virol. 2004 Mar;78(6):2863-74
14990705
Am J Respir Cell Mol Biol. 1993 Nov;9(5):547-56
7692897
Hum Gene Ther. 1998 Apr 10;9(6):889-909
9581911
J Clin Invest. 2000 Jun;105(11):1573-87
10841516
Blood. 2006 Mar 15;107(6):2548-56
16291597
Cells Tissues Organs. 2004;177(3):139-50
15388988
J Virol. 2000 Apr;74(8):3852-8
10729159
Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):12993-8
16938846
Biochem Biophys Res Commun. 2004 Sep 17;322(2):447-51
15325250
FEBS Lett. 1998 Jun 16;429(3):269-73
9662430
J Virol. 2007 Feb;81(4):2069-73
17151095
Nat Biotechnol. 2000 May;18(5):527-32
10802620
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11854-9
12192090
J Biol Chem. 1999 Oct 1;274(40):28652-9
10497234
Int J Pharm. 2000 Nov 4;208(1-2):1-11
11064206
J Virol. 1998 Feb;72(2):1438-45
9445046
Am J Physiol. 1994 Jan;266(1 Pt 1):C254-68
7508190
J Virol. 1999 Jul;73(7):6085-8
10364362
J Biol Chem. 2007 Jan 19;282(3):1805-18
17098740
J Biol Chem. 1992 Mar 15;267(8):5575-83
1372005
Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2952-7
15703296
Am J Respir Cell Mol Biol. 1994 Jan;10(1):38-47
7507342
J Virol. 2000 Oct;74(19):9281-93
10982375
Gene Ther. 2003 Jul;10(14):1142-51
12833123
FEBS Lett. 2001 Feb 2;489(2-3):263-9
11165262
Mol Ther. 2003 Dec;8(6):999-1008
14664803
J Clin Invest. 2002 Aug;110(4):499-504
12189244
J Virol. 2003 Jul;77(13):7361-6
12805434
J Virol. 2003 Jun;77(12):6995-7006
12768018
Curr Opin Mol Ther. 2006 Oct;8(5):439-45
17078386
J Immunol. 2000 Jan 1;164(1):427-35
10605039
Nat Biotechnol. 2002 Jul;20(7):697-701
12089554
Hum Gene Ther. 1998 Dec 10;9(18):2761-76
9874274
Hum Gene Ther. 2005 May;16(5):541-50
15916479
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6716-21
10841568